Pay in 4 interest-free payments of $16.25 Learn more
Ships within 48 hours · Estimated delivery Jul 26 - Jul 31
Currently CI994 is in phase III clinical trials for lung cancer
Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor
InChiKey: WEVYNIUIFUYDGI-UHFFFAOYSA-N
promote PKM2 tetramer formation and prevent inhibition by phosphotyrosine signaling
RGFP966 was used at 10 µM final concentration in various in vitro assays
OG-L002 - LSD1 Inhibitor. CAS# 1357302-64-7 60281 Currently CI994 is in phaseOG L002, CAS No. 1357302 64 7, is a highly potent and specific inhibitor of Lysine Specific Demethylase 1 (LSD1). It inhibits LSD1 in biochemical assay with an IC50 ~20 nM, and has moderate inhibitory activity against monoamine oxidases MAO A and MAO B with IC50 ~1. 38 M and 0. 72M respectively. It potently repressed herpes simplex virus (HSV) IE gene expression, genome replication, and reactivation from latency. OG L002 suppressed primary lytic